There is increasing interest in regulating redox signaling in DMD, with NRF2 activation and NF‐κB inhibition identified as potential therapeutic targets (Kourakis et al., 2021; Messina et al., 2011). The gene discussed is NFKB1; the disease is Duchenne muscular dystrophy.